Related Experiment Video
Updated: Jul 7, 2026

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
Induction of p21 by p65 in p53 null cells treated with Doxorubicin
Shenglin Ma1, Juanjuan Tang, Jianguo Feng
1Zhejiang Tumor Hospital, Banshanqiao,Hangzhou, Zhejiang Province, China.
Abstract:
NFkappaB/p65 is a transcription factor that can protect or contribute to cell death. Here we show that knockdown of p65 by IkappaBSR or p65 siRNA decreased the cytotoxic effect of DOX on HCT116 (p53+/+) cells, correlating with increased induction of p21. In previous work, we demonstrated that p21 suppressed cell death via its CDK-inhibitory activity. Thus, we propose that the p65 activity is required for p53-dependent cell death through limitation of p53-induced p21 expression. In HCT116 (p53-/-) cells, downregulation of p65 expression enhanced the cytotoxic effect of DOX, due to decreased p21 expression levels. We present evidence that in p53-null tumor cells treated with DOX, p65 was involved in induction of p21 expression by directly binding to the p21 promoter. Our data suggested that both p53 and p65 limited each other's ability to stimulate p21 induction and this mutual repression mechanism was consistent with a model in which both factors were competing for limiting pool of p300/CBP coactivator protein complexes. These findings indicate an association between p21 expression and resistance to cell death through p65, a novel regulatory mechanism in which p21 bridges a transcriptional crosstalk between p53 and p65.
Insights
Nuclear factor kappa B (NFkappaB)/p65 influences cancer cell death by regulating p21 expression. This study reveals p65 is crucial for p53-dependent cell death, impacting p21 levels and chemotherapy response.
Area of Science:
- Molecular Biology
- Cancer Research
- Cellular Signaling
Background:
- Nuclear factor kappa B (NFkappaB)/p65 is a transcription factor with dual roles in cell survival and death.
- Previous research established p21's role in suppressing cell death through cyclin-dependent kinase (CDK) inhibition.
Purpose of the Study:
- To investigate the role of NFkappaB/p65 in doxorubicin (DOX)-induced cell death in HCT116 cells.
- To elucidate the regulatory relationship between p53, p65, and p21 expression in response to chemotherapy.
Main Methods:
- Knockdown of p65 using IkappaBSR or p65 siRNA in HCT116 cells with varying p53 statuses.
- Assessment of doxorubicin (DOX) cytotoxicity and p21 expression levels.
- Analysis of p65 binding to the p21 promoter via chromatin immunoprecipitation.
Main Results:
- p65 knockdown decreased DOX cytotoxicity in p53-positive cells, correlating with increased p21 induction.
- p65 downregulation enhanced DOX cytotoxicity in p53-null cells, linked to decreased p21 expression.
- Evidence suggests p65 directly binds the p21 promoter in p53-null cells.
Conclusions:
- p65 activity is required for p53-dependent cell death by limiting p53-induced p21 expression.
- A novel mechanism exists where p53 and p65 mutually repress p21 induction, potentially through competition for p300/CBP coactivators.
- p21 acts as a bridge in the transcriptional crosstalk between p53 and p65, influencing chemoresistance.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Inhibition of Cdk Activity
The Intrinsic Apoptotic Pathway

